Can Red Light Therapy Help Fibromyalgia?
What the evidence suggests, where it fits, and how I would think about it
Fibromyalgia is one of the clearest examples of how pain can take over a life without leaving obvious damage on a scan. That is part of what makes patients so vulnerable to both dismissal and overpromising. Red light therapy (photobiomodulation, or PBM) is interesting because it may help some people, but the real question is not whether it sounds futuristic. It is whether it meaningfully improves day-to-day function.
I also walk through this step-by-step here (video):
What This Really Means
The best way to think about red light therapy for fibromyalgia is as a potentially useful adjunct, not a miracle treatment. A 2019 meta-analysis pooled 9 randomized trials involving 325 patients and found improvements versus placebo across pain, Fibromyalgia Impact Questionnaire scores, tender points, fatigue, stiffness, anxiety, and depression, although the underlying studies were small and methodologically mixed.
More recent whole-body photobiomodulation trials have also reported improvements in pain and quality of life after about 4 weeks of treatment. At the same time, fibromyalgia guidelines still place exercise, education, and broader nonpharmacologic care at the center of treatment, which is why I think of light therapy as a way to widen the window for recovery rather than replace the fundamentals.
My Clinical Framework on Light-Based Adjuncts for Fibromyalgia
Start with the bottleneck. I ask what is most disabling right now: pain, post-exertional flare, nonrestorative sleep, or fear of movement. Fibromyalgia treatment works better when the main barrier is identified early.
Use light therapy when pain is blocking re-entry into activity. The most clinically interesting patient is not the one already doing well with exercise, but the person whose pain is still too high to restart walking, stretching, or strengthening.
Judge it by function, not novelty. I would track whether the patient can move more, flare less, or wake slightly more restored over 2 to 4 weeks. Immediate “feels good” impressions are less useful than a functional trend.
Do not let it become passive care. If a treatment lowers symptoms but never gets translated into better pacing, sleep habits, and graduated movement, the long-term value is usually limited.
What I’d Do If This Were Me or My Family
I would consider a time-limited trial of clinic-grade photobiomodulation if fibromyalgia pain were preventing normal movement and if standard approaches had only partly helped. I would be much less eager to spend heavily on a consumer device up front, because the better evidence so far comes from supervised clinical protocols with repeated sessions over several weeks, not from home gadgets marketed directly to patients.
Key Numbers That Matter
9 randomized trials and 325 patients were included in the 2019 meta-analysis.
4 weeks of treatment is a common duration in newer whole-body trials.
12 sessions, often given 3 times per week, is a common whole-body protocol.
660 nm and 850 nm are among the most commonly studied wavelengths in newer whole-body systems.
Exercise remains the only strong therapy-based recommendation in the EULAR guideline framework.
Biggest Mistake I See Patients Make
Treating red light therapy as if it should replace the rest of fibromyalgia care. The better question is not “Did my pain score dip after treatment?” but “Did this help me move, sleep, and function a little better over the next several weeks?”
Who This Applies To (and Who It Doesn’t)
Applies to:
People with fibromyalgia whose pain or fatigue is preventing them from re-entering exercise or physical therapy.
People who want a non-drug option added to a broader plan, not substituted for one.
People who can assess progress by function, not only by how they feel during a session.
May not apply to:
People expecting a one-session fix or a stand-alone cure.
People ready to spend large amounts on consumer devices when the stronger evidence base comes from supervised, protocol-driven treatment.
A Test Worth Discussing With Your Doctor
A sleep study may be worth discussing if you have loud snoring, witnessed apneas, prominent daytime sleepiness, or severe nonrestorative sleep. In fibromyalgia, untreated sleep apnea can overlap with and amplify fatigue, pain sensitivity, and cognitive fog, so sometimes the most useful next step is not another supplement or gadget, but identifying a treatable sleep disorder.
If You Only Remember One Thing, Remember This
Red light therapy is most promising as a bridge that may help some people with fibromyalgia regain function, not as a cure by itself.
My Take / My Bias
I am generally favorable toward low-risk treatments when the claims are modest and the evidence is directionally encouraging. I am much less favorable when a decent adjunct gets marketed as a breakthrough. In fibromyalgia, I trust treatments more when they help patients re-enter life, not when they simply create another expensive ritual around pain.
If you’d like to see how I walk through this step-by-step:
Fibromyalgia is a condition in which patients are often forced to sort through too much false hope and too little thoughtful guidance, so I hope this helped clarify where red light therapy may genuinely fit.
If you know someone who might find this useful, feel free to pass it along. Paid members are also welcome to leave questions or comments below.
To your health,
-Dr. Haque
P.S. What I’m Reading This Week
New US cholesterol guideline recommends earlier screening and statin treatment
A recent news piece highlights a new U.S. cholesterol guideline that pushes clinicians to start earlier, individualize more, and pay closer attention to lifetime cardiovascular risk.
Why it matters: Prevention is slowly shifting away from waiting for late disease and toward identifying risk sooner, which is exactly where medicine is often most effective.
Lilly reports trial results for retatrutide in diabetes
STAT recently covered late-stage trial results suggesting that retatrutide produced meaningful reductions in both HbA1c and body weight in people with diabetes.
Why it matters: The obesity and metabolic-treatment landscape is moving quickly, and the practical question is no longer whether these drugs matter, but how to compare efficacy, tolerability, cost, and long-term strategy.
MASALA Study Suggests Earlier Cardiovascular Vigilance Needed for People With South Asian Ancestry
MASALA Study-related findings suggesting earlier and more tailored cardiovascular vigilance may be warranted in South Asian populations.
Why it matters: Good prevention increasingly depends on understanding that risk is not distributed evenly across ancestry populations, and that “average-risk” thinking can miss real disease, especially when BMI is the focus.
**
Scholarly References on Photobiomodulation for Fibromyalgia
Yeh, S.-W., Hong, C.-H., Shih, M.-C., Tam, K.-W., Huang, Y.-H., & Kuan, Y.-C. (2019). Low-level laser therapy for fibromyalgia: A systematic review and meta-analysis. Pain Physician, 22(3), 241-254.
Navarro-Ledesma, S., Carroll, J., Burton, P., & González-Muñoz, A. (2023). Short-term effects of whole-body photobiomodulation on pain, quality of life and psychological factors in a population suffering from fibromyalgia: A triple-blinded randomised clinical trial. Pain and Therapy, 12(1), 225-239.
Navarro-Ledesma, S., Carroll, J. D., González-Muñoz, A., & Burton, P. (2024). Outcomes of whole-body photobiomodulation on pain, quality of life, leisure physical activity, pain catastrophizing, kinesiophobia, and self-efficacy: A prospective randomized triple-blinded clinical trial with 6 months of follow-up. Frontiers in Neuroscience, 18, Article 1264821.
Fitzmaurice, B. C., Heneghan, N. R., Rayen, A. T. A., Grenfell, R. L., & Soundy, A. A. (2023). Whole-body photobiomodulation therapy for fibromyalgia: A feasibility trial. Behavioral Sciences, 13(9), Article 717.
Macfarlane, G. J., Kronisch, C., Dean, L. E., Atzeni, F., Häuser, W., Fluß, E., Choy, E., Kosek, E., Amris, K., Branco, J., Dincer, F., Leino-Arjas, P., Longley, K., McCarthy, G. M., Makri, S., Perrot, S., Sarzi-Puttini, P., Taylor, A., & Jones, G. T. (2017). EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases, 76(2), 318-328.